Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

ADC Therapeutics' Claudin-6 Targeting ADC Shows Strong Single-Agent And Combination Potential In Solid Tumors

Author: Benzinga Newsdesk | April 28, 2025 07:09am

Oral presentation shows ADCT-242 targeting Claudin-6 was well-tolerated and demonstrated potent antitumor activity in ovarian and non-small lung cancer
Poster presentations highlight antitumor activity and safety of novel PSMA-targeted and ASCT2- targeted ADCs

Posted In: ADCT